SERA (Sera Prognostics) ROC (Joel Greenblatt) %: -2,992.25% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SERA Sera Prognostics Inc SERA
69 GF Score
Price $2.05
GF Value $1.83
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Sera Prognostics ROC (Joel Greenblatt) %?

Sera Prognostics SERA -5.96% 69 ROC (Joel Greenblatt) % is -2,992.25% as of Mar. 2026. GuruFocus rates SERA with a GF Score™ of 69/100 and a GF Value™ of $1.83 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 838 Medical Devices & Instruments companies, Sera Prognostics ranks worse than 97.26% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Sera Prognostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2,992.25%.

The historical rank and industry rank for Sera Prognostics's ROC (Joel Greenblatt) % or its related term are showing as below:

SERA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2773.43   Med: -1826.37   Max: -889.85
Current: -2773.43

During the past 7 years, Sera Prognostics's highest ROC (Joel Greenblatt) % was -889.85%. The lowest was -2773.43%. And the median was -1826.37%.

SERA's ROC (Joel Greenblatt) % is ranked worse than
97.26% of 838 companies
in the Medical Devices & Instruments industry
Industry Median: 4.415 vs SERA: -2773.43

Sera Prognostics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -7.10% per year.


Sera Prognostics  (NAS:SERA) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Sera Prognostics ROC (Joel Greenblatt) % Related Terms


Sera Prognostics ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Sera Prognostics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sera Prognostics ROC (Joel Greenblatt) % Chart

Sera Prognostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -2,502.78 -1,826.37 -1,430.88 -2,030.27 -2,673.28

Sera Prognostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,566.21 -2,557.71 -2,794.99 -2,890.42 -2,992.25

SERA vs LNSR, ECOR, SNWV: ROC (Joel Greenblatt) % Comparison

For the Medical Devices subindustry, Sera Prognostics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sera Prognostics ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Sera Prognostics's ROC (Joel Greenblatt) % falls into.


SERA
69GF Score
Sera Prognostics Inc SERA
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sera Prognostics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.012 + 0 + 1.557) - (0.862 + 20.315 + 3.009)
=-22.617

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.011 + 0 + 2.314) - (1.109 + 20.31 + 2)
=-21.094

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Sera Prognostics for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-33.588/( ( (1.149 + max(-22.617, 0)) + (1.096 + max(-21.094, 0)) )/ 2 )
=-33.588/( ( 1.149 + 1.096 )/ 2 )
=-33.588/1.1225
=-2,992.25 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -2,992.25% mean?
Sera Prognostics (SERA) has a ROC (Joel Greenblatt) % of -2,992.25% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sera Prognostics and its competitors. According to the industry distribution chart, Sera Prognostics ranks #815 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 97.3%.
Is Sera Prognostics' ROC (Joel Greenblatt) % too high?
Sera Prognostics' current ROC (Joel Greenblatt) % is -2,992.25%. Based on the distribution chart, Sera Prognostics ranks #815 out of 838 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sera Prognostics has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sera Prognostics' ROC (Joel Greenblatt) % compare to LNSR and ECOR?
According to the Medical Devices & Instruments industry distribution chart, Sera Prognostics ranks #815 out of 838 companies for ROC (Joel Greenblatt) %. This places Sera Prognostics in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 4.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.42, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sera Prognostics and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sera Prognostics's current ROC (Joel Greenblatt) % is -2,992.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sera Prognostics stock overvalued right now?
Based on GuruFocus' analysis, Sera Prognostics (SERA) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.83, compared to a current price of $2.05 — trading 12% above its estimated fair value. The current ROC (Joel Greenblatt) % is -2,992.25%. Sera Prognostics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Sera Prognostics (SERA), the current ROC (Joel Greenblatt) % is -2,992.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sera Prognostics (SERA) Overvalued in 2026?

Based on GuruFocus' analysis, Sera Prognostics stock appears to be overvalued. The current stock price of $2.05 is trading 12% above its estimated GF Value™ of $1.83. GuruFocus considers Sera Prognostics to be Modestly Overvalued.

Key valuation signals for SERA:

  • ROC (Joel Greenblatt) %: -2,992.25%
  • GF Value™: $1.83 vs. price of $2.05 (12% above fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sera Prognostics Business Description

Address 2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
69GF Score

Get the complete analysis for SERA

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.05
Price
$1.83
GF Value